Health
Life-extending breast cancer drug finally approved for NHS in England
England has approved Enhertu for NHS use two years after initial cost rejections, following a revised pricing framework and sustained patient campaigns.
England has approved Enhertu for NHS use two years after initial cost rejections, following a revised pricing framework and sustained patient campaigns.
Researchers reveal a new function of the tumor suppressor Rb, which unexpectedly boosts estrogen receptor signaling and aids breast cancer cell proliferation.